Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07314470 in healthy volunteers
NCT06821750Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Feb 2025
- Primary completion
- Aug 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07314470 (4 arms), sponsored by Pfizer. Primary endpoints: Treatment Emergent Adverse Events at 35 days, Clinically Significant Change from Baseline in Laboratory Values at 35 days and 3 more. Started Feb 2025; status: terminated.
02
Drugs
PF-07314470
Beyond the preview
Go deeper on NCT06821750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821750.